Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 343 | 62 | 275 |
| Samples | 335 | 59 | 270 |
| Peptides | 141 | 34 | 114 |
Function
PSMB11 · Proteasome subunit beta 11
Proteasomes generate peptides that are presented by major histocompatibility complex (MHC) I molecules to other cells of the immune system. Proteolysis is conducted by 20S proteasomes, complexes of 28 subunits arranged as a cylinder in 4 heteroheptameric rings: alpha-1 to -7, beta-1 to -7, beta-1 to -7, and alpha-1 to -7. The catalytic subunits are beta-1 (PSMB6; MIM 600307), beta-2 (PSMB7; MIM 604030), and beta-5 (PSMB5; MIM 600306). Three additional subunits, beta-1i (PSMB9; MIM 177045), beta-2i (PSMB10; MIM 176847), and beta-5i (PSMB8; MIM 177046), are induced by gamma-interferon (IFNG; MIM 147570) and are preferentially incorporated into proteasomes to make immunoproteasomes. PSMB11, or beta-5t, is a catalytic subunit expressed exclusively in cortical thymic epithelial cells (Murata et al., 2007 [PubMed 17540904]).[supplied by OMIM, Mar 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000408907 | A5LHX3 | 343 | 141 |
Gene Properties
Recurrent Mutations
All 141 amino-acid changes on canonical ENST00000408907 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PSMB11 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PSMB11 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 79/2550 3% |
| Other Solid Cancers | 2/94 2% | 45/1515 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 11/612 2% |
| Non-Small Cell Lung Carcinoma | 18/304 6% | 11/1390 1% |
| Neuroendocrine Tumour | 3/154 2% | 8/577 1% |
| Melanoma | 2/210 1% | 24/1899 1% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 4/810 0% |
| Gastric Carcinoma | 2/74 3% | 15/1809 1% |
| Colorectal Carcinoma | 4/143 3% | 26/3239 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Cervical Carcinoma | 1/35 3% | 1/422 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Other Sarcomas | 1/69 1% | 2/699 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Breast Carcinoma | 4/144 3% | 7/3264 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Bladder Carcinoma | 2/58 3% | 1/956 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Wilms Tumour | 0/5 0% | 1/474 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 2/1592 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 4/2640 0% |
Mutation Distribution
Where PSMB11 is mutated · all tissues, split by cell line vs tissue
How many mutations in PSMB11 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 17 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 343 mutations in PSMB11
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|